Skip to Main Content

Paper Details

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
Clin Cancer Res
20
2022
Author NameAffiliation
Ronald de WitErasmus MC Cancer Institute
Yves FradetCentre Hospitalier Universitaire de Quebec-Universite Laval
Lawrence Fonguniversity of california los angeles
Cora N SternbergEnglander Institute for Precision Medicine, Meyer Cancer Center
Toni K ChoueiriDana-Farber Cancer Institute
David I QuinnUSC Norris Comprehensive Cancer Center
Andrey LobodaMerck & Co., Inc.
  • 1 - 7

Datasets

Release 1.2